Y90 Selective Internal Radiation Therapy

Selective internal radiation therapy using yttrium-90 resin microspheres in patients with unresectable hepatocellular carcinoma: a retrospective study

“…The procedure was generally well tolerated. The median OS for all patients in this analysis was 13.1 months, similar to the median OS of 13.2 months in a retrospective study of 30 Asian patients with inoperable HCC who were treated with Y-90 resin SIRT (19) and longer than the median OS of 10.7 months for patients with unresectable HCC treated with sorafenib (15) and 10.6 months for patients with unresectable HCC treated with regorafenib after progression on sorafenib (13) seen in phase 3 trials of these drugs.…”

“…Y-90 resin SIRT has been shown to increase median OS in patients with HCC (16,19), but which of the many specific patient and disease characteristics might predict response is not known. In this retrospective study, we examined survival outcomes in a large number of patients with unresectable HCC who were treated with Y-90 resin SIRT at a single tertiary referral center.…”

A Review and Update of Treatment Options and Controversies in the Management of Hepatocellular Carcinoma

“…64,65 The major indications for TARE include patients with nonmetastatic unresectable HCC who are not candidates for transplantation or ablation. 64,65 The major indications for TARE include patients with nonmetastatic unresectable HCC who are not candidates for transplantation or ablation.…”

Contribution of Computed Tomographic Angiography to Pretreatment Planning of Radio-embolization of Liver Tumors

“…Moreover, mapping the distance of normal arterial branches from the point of microsphere application is also important, especially for the gastroduodenal and cystic arteries (10). Specifically, up to 17% of tumors located on the liver surface have a parasitic arterial supply (Table II) (11).…”